This company’s main dialysis infection product still looks hard to replace, but the market seems to be pricing it as if growth has stalled for good. A pricing change and two upcoming trial readouts could reshape the story quickly, with big upside if things go right—and a clear hit if they don’t.Read more
CorMedix is betting that buying Melinta and folding its hospital sales network into the business helps it sell more infection-fighting medicines and lean less on a single product. The big question is whether the deal and new drug uses come through as planned—or whether debt, pricing pressure, and tough approvals get in the way.Read more
Catalysts About CorMedix CorMedix develops and commercializes specialty therapies that prevent and treat life threatening infections in high risk hospital and clinic patients. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About CorMedix CorMedix develops and commercializes differentiated therapies that prevent and treat serious, life-threatening infections in acute care settings. What are the underlying business or industry changes driving this perspective?Read more
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
